(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Nikola, MIND Technology, and Lipocine.

Rank	Financial Asset	Price	Change	Updated (EST)
1	Nikola (NKLA)	1.09	19.68%	2023-06-14 14:45:26
2	MIND Technology (MIND)	0.78	18.61%	2023-06-14 07:11:08
3	Lipocine (LPCN)	4.92	12.84%	2023-06-14 01:14:06
4	Martin Midstream Partners L.P. (MMLP)	2.39	10.14%	2023-06-14 07:17:08
5	Minerva Neurosciences (NERV)	7.32	7.95%	2023-06-14 11:14:07
6	Li Auto (LI)	33.88	7.57%	2023-06-14 14:45:10
7	Lumen Technologies (LUMN)	2.28	6.95%	2023-06-14 10:47:43
8	NN (NNBR)	2.10	5.53%	2023-06-14 12:23:08
9	Nike (NKE)	112.56	5.41%	2023-06-14 13:43:05
10	Smith & Nephew (SNN)	31.50	5.33%	2023-06-14 14:51:46

The three biggest losers today are MicroVision, Methes Energies International Ltd, and Ocular Therapeutix.

Rank	Financial Asset	Price	Change	Updated (EST)
1	MicroVision (MVIS)	4.55	-28.57%	2023-06-14 14:56:58
2	Methes Energies International Ltd (MEIL)	0.02	-18.89%	2023-06-14 05:10:08
3	Ocular Therapeutix (OCUL)	5.31	-16.38%	2023-06-14 16:17:07
4	Humana (HUM)	447.33	-12.74%	2023-06-14 13:41:24
5	Logitech (LOGI)	56.85	-11.03%	2023-06-14 14:56:29
6	American Public Education (APEI)	4.52	-10.85%	2023-06-14 14:53:16
7	FuelCell Energy (FCEL)	2.57	-8.06%	2023-06-14 14:55:01
8	CVS Health (CVS)	67.12	-7.11%	2023-06-14 13:39:35
9	Aurora Cannabis (ACB)	0.54	-7.05%	2023-06-14 10:47:38
10	FibroGen (FGEN)	16.34	-6.95%	2023-06-14 14:55:05

Winners today

1. Nikola (NKLA) – 19.68%

Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions. It operates through two business units, Truck and Energy. The Truck business unit develops and commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. The Energy business unit develops and constructs a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. The company also assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.

NASDAQ ended the session with Nikola rising 19.68% to $1.09 on Wednesday, after five sequential sessions in a row of gains. NASDAQ jumped 0.39% to $13,626.48, after four sequential sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Nikola has a trailing twelve months EPS of $-2.23.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -137.05%.

Sales Growth

Nikola’s sales growth is negative 16.8% for the present quarter and 37.9% for the next.

Volume

Today’s last reported volume for Nikola is 113764000 which is 253.54% above its average volume of 32177800.

More news about Nikola.

2. MIND Technology (MIND) – 18.61%

MIND Technology, Inc., together with its subsidiaries, provides technology to the oceanographic, hydrographic, defense, seismic and maritime security industries. It develops, manufactures, and sells proprietary products. The company's products include the GunLink seismic source acquisition and control systems that provide operators of marine seismic surveys with precise monitoring and control of energy sources; the BuoyLink RGPS tracking system, which is used to offer precise positioning of marine seismic energy sources and streamers; Digishot energy source controllers; Sleeve Gun energy sources; and SeaLink product line of marine sensors and solid streamer systems. It also provides streamer weight collars, depth and pressure transducers, air control valves, and source array systems; spare and replacement parts; and repair and engineering services, training and field service operations, and umbilical terminations, as well as side scan sonar systems and related products. The company markets its products to governmental and commercial customers through internal sales organization and a network of distributors and representatives. It serves in in the United States, Europe, Russia, CIS, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. The company was formerly known as Mitcham Industries, Inc. MIND Technology, Inc. was incorporated in 1987 and is headquartered in The Woodlands, Texas.

NASDAQ ended the session with MIND Technology rising 18.61% to $0.78 on Wednesday while NASDAQ jumped 0.39% to $13,626.48.

Earnings Per Share

As for profitability, MIND Technology has a trailing twelve months EPS of $-0.86.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -27.88%.

More news about MIND Technology.

3. Lipocine (LPCN) – 12.84%

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH); TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

NASDAQ ended the session with Lipocine jumping 12.84% to $4.92 on Wednesday, after two successive sessions in a row of gains. NASDAQ rose 0.39% to $13,626.48, after four consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Lipocine has a trailing twelve months EPS of $-2.16.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -29.96%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Lipocine’s EBITDA is -26.85.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is a negative 25.5% and a negative 13.7%, respectively.

More news about Lipocine.

4. Martin Midstream Partners L.P. (MMLP) – 10.14%

Martin Midstream Partners L.P., together with its subsidiaries, engages in terminalling, processing, storage, and packaging of petroleum products and by-products primarily in the United States Gulf Coast region. The company's Terminalling and Storage segment owns or operates 17 marine shore-based terminal facilities and 13 specialty terminal facilities that provide storage, refining, blending, packaging, and handling services for producers and suppliers of petroleum products and by-products. This segment also offers land rental services to oil and gas companies, as well as storage and handling services for lubricants and fuels. Its Transportation segment operates a fleet of 560 tank trucks and 1,150 trailers; and 31 inland marine tank barges, 14 inland push boats, and 1 articulated offshore tug and barge unit to transport petroleum products and by-products, petrochemicals, and chemicals. The company's Sulfur Services segment processes molten sulfur into prilled or pelletized sulfur, which is used in the production of fertilizers and industrial chemicals. This segment also owns 21 railcars and leases 27 railcars to transport molten sulfur; and leases 131 railcars to transport fertilizer products. Its Natural Gas Liquids segment stores, distributes, and transports natural gas liquids for wholesale deliveries to refineries, industrial NGL users, and propane retailers, as well as owns approximately 2.1 million barrels of underground storage capacity for NGLs. Martin Midstream GP LLC serves as a general partner of the company. Martin Midstream Partners L.P. was founded in 2002 and is based in Kilgore, Texas.

NASDAQ ended the session with Martin Midstream Partners L.P. rising 10.14% to $2.39 on Wednesday, following the last session’s upward trend. NASDAQ rose 0.39% to $13,626.48, after four sequential sessions in a row of gains, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Martin Midstream Partners L.P. has a trailing twelve months EPS of $-0.68.

Revenue Growth

Year-on-year quarterly revenue growth declined by 12.4%, now sitting on 984.21M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Martin Midstream Partners L.P.’s EBITDA is 0.62.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on May 4, 2023, the estimated forward annual dividend rate is 0.02 and the estimated forward annual dividend yield is 0.92%.

Yearly Top and Bottom Value

Martin Midstream Partners L.P.’s stock is valued at $2.39 at 17:32 EST, way below its 52-week high of $4.75 and way higher than its 52-week low of $1.95.

More news about Martin Midstream Partners L.P..

5. Minerva Neurosciences (NERV) – 7.95%

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

NASDAQ ended the session with Minerva Neurosciences jumping 7.95% to $7.32 on Wednesday while NASDAQ jumped 0.39% to $13,626.48.

Earnings Per Share

As for profitability, Minerva Neurosciences has a trailing twelve months EPS of $-5.35.

Yearly Top and Bottom Value

Minerva Neurosciences’s stock is valued at $7.32 at 17:32 EST, way below its 52-week high of $15.27 and way higher than its 52-week low of $1.26.

Volume

Today’s last reported volume for Minerva Neurosciences is 175857 which is 10.42% below its average volume of 196330.

Moving Average

Minerva Neurosciences’s worth is way higher than its 50-day moving average of $4.80 and way higher than its 200-day moving average of $4.42.

More news about Minerva Neurosciences.

6. Li Auto (LI) – 7.57%

Li Auto Inc., through its subsidiaries, designs, develops, manufactures, and sells new energy vehicles in the People's Republic of China. The company provides Li ONE and Li L series smart electric vehicles. It also offers sales and after sales management, and technology development and corporate management services, as well as purchases manufacturing equipment. The company offers its products through online and offline channels. The company was formerly known as Leading Ideal Inc. and changed its name to Li Auto Inc. in July 2020. Li Auto Inc. was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Li Auto rising 7.57% to $33.88 on Wednesday while NASDAQ jumped 0.39% to $13,626.48.

Earnings Per Share

As for profitability, Li Auto has a trailing twelve months EPS of $-0.16.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -2.47%.

More news about Li Auto.

7. Lumen Technologies (LUMN) – 6.95%

Lumen Technologies, Inc., a facilities-based technology and communications company, provides various integrated products and services under the Lumen, Quantum Fiber, and CenturyLink brands to business and residential customers in the United States and internationally. The company operates in two segments, Business and Mass Markets. It offers compute and application services, such as edge cloud services, IT solutions, unified communication and collaboration solutions, colocation and data center services, content delivery services, and managed security services; and IP and data services, including VPN data network, Ethernet, internet protocol (IP), and voice over internet protocol. The company also provides fiber infrastructure services comprising high bandwidth optical wavelength networks; and unlit optical fiber and related professional services. In addition, it offers voice and other services, including private line services, a direct circuit or channel specifically dedicated for connecting two or more organizational sites; a portfolio of traditional time division multiplexing voice services; and synchronous optical network-based ethernet, legacy data hosting services, and conferencing services. The company was formerly known as CenturyLink, Inc. and changed its name to Lumen Technologies, Inc. in September 2020. The company was incorporated in 1968 and is headquartered in Monroe, Louisiana.

NYSE ended the session with Lumen Technologies rising 6.95% to $2.28 on Wednesday while NYSE slid 0.16% to $15,642.73.

Earnings Per Share

As for profitability, Lumen Technologies has a trailing twelve months EPS of $-1.57.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Lumen Technologies’s stock is considered to be oversold (<=20).

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 220% and a negative 35.7%, respectively.

Volume

Today’s last reported volume for Lumen Technologies is 17089500 which is 37.22% below its average volume of 27222700.

Volatility

Lumen Technologies’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.19%, a negative 1.39%, and a positive 3.31%.

Lumen Technologies’s highest amplitude of average volatility was 2.05% (last week), 4.01% (last month), and 3.31% (last quarter).

More news about Lumen Technologies.

8. NN (NNBR) – 5.53%

NN, Inc., a diversified industrial company, designs, manufactures, and sells high-precision components and assemblies primarily for the electrical, automotive, general industrial, aerospace and defense, and medical markets. It operates through Mobile Solutions and Power Solutions segments. The Mobile Solutions segment manufactures and sells system critical components for fuel systems, engines and transmissions, power steering systems, and electromechanical motors for general industrial and automotive end markets. The Power Solutions segment designs, manufactures, and sells a range of high-precision metal and plastic components, assemblies, and finished devices used in applications ranging from power control to flight control and for military devices. Its products include electrical contacts, connectors, contact assemblies, and precision stampings for the electrical end market; and high precision products for the aerospace and defense end markets. This segment also produces various tools and instruments for the orthopaedics and medical/surgical end markets. The company sells its products worldwide primarily to manufacturers directly. NN, Inc. was founded in 1980 and is headquartered in Charlotte, North Carolina.

NASDAQ ended the session with NN jumping 5.53% to $2.10 on Wednesday, following the last session’s downward trend. NASDAQ jumped 0.39% to $13,626.48, after four consecutive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, NN has a trailing twelve months EPS of $-1.04.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.42%.

Volume

Today’s last reported volume for NN is 71689 which is 80.32% below its average volume of 364326.

Yearly Top and Bottom Value

NN’s stock is valued at $2.10 at 17:32 EST, way under its 52-week high of $2.97 and way above its 52-week low of $0.97.

Revenue Growth

Year-on-year quarterly revenue growth declined by 0.8%, now sitting on 497.76M for the twelve trailing months.

Sales Growth

NN’s sales growth is 5% for the ongoing quarter and 6% for the next.

More news about NN.

9. Nike (NKE) – 5.41%

NIKE, Inc., together with its subsidiaries, designs, develops, markets, and sells men's, women's, and kids athletic footwear, apparel, equipment, and accessories worldwide. The company provides athletic and casual footwear, apparel, and accessories under the Jumpman trademark; and casual sneakers, apparel, and accessories under the Converse, Chuck Taylor, All Star, One Star, Star Chevron, and Jack Purcell trademarks. In addition, it sells a line of performance equipment and accessories comprising bags, socks, sport balls, eyewear, timepieces, digital devices, bats, gloves, protective equipment, and other equipment for sports activities under the NIKE brand; and various plastic products to other manufacturers. The company markets apparel with licensed college and professional team, and league logos, as well as sells sports apparel. Additionally, it licenses unaffiliated parties to manufacture and sell apparel, digital devices, and applications and other equipment for sports activities under NIKE-owned trademarks. The company sells its products to footwear stores; sporting goods stores; athletic specialty stores; department stores; skate, tennis, and golf shops; and other retail accounts through NIKE-owned retail stores, digital platforms, independent distributors, licensees, and sales representatives. The company was formerly known as Blue Ribbon Sports, Inc. and changed its name to NIKE, Inc. in 1971. NIKE, Inc. was founded in 1964 and is headquartered in Beaverton, Oregon.

NYSE ended the session with Nike jumping 5.41% to $112.56 on Wednesday while NYSE slid 0.16% to $15,642.73.

Earnings Per Share

As for profitability, Nike has a trailing twelve months EPS of $3.47.

PE Ratio

Nike has a trailing twelve months price to earnings ratio of 32.44. Meaning, the purchaser of the share is investing $32.44 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 37.34%.

Yearly Top and Bottom Value

Nike’s stock is valued at $112.56 at 17:32 EST, way under its 52-week high of $131.31 and way higher than its 52-week low of $82.22.

More news about Nike.

10. Smith & Nephew (SNN) – 5.33%

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products, including instruments, technologies, and implants to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

NYSE ended the session with Smith & Nephew jumping 5.33% to $31.50 on Wednesday, after two successive sessions in a row of gains. NYSE fell 0.16% to $15,642.73, after two sequential sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Smith & Nephew has a trailing twelve months EPS of $0.51.

PE Ratio

Smith & Nephew has a trailing twelve months price to earnings ratio of 61.77. Meaning, the purchaser of the share is investing $61.77 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.12%.

Volatility

Smith & Nephew’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.39%, a negative 0.34%, and a positive 0.92%.

Smith & Nephew’s highest amplitude of average volatility was 0.81% (last week), 0.87% (last month), and 0.92% (last quarter).

Yearly Top and Bottom Value

Smith & Nephew’s stock is valued at $31.50 at 17:32 EST, under its 52-week high of $33.09 and way above its 52-week low of $21.78.

More news about Smith & Nephew.

Losers Today

1. MicroVision (MVIS) – -28.57%

MicroVision, Inc. develops and sells lidar sensors used in automotive safety and autonomous driving applications. Its laser beam scanning technology is based on micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company also develops micro-display concepts and designs for head-mounted augmented reality (AR) headsets, as well as 1440i MEMS module supporting AR headsets; interactive display solutions for the smart speakers market; and Consumer Lidar used in smart home systems. In addition, it develops 1st Generation LRL module. The company sells its products primarily to original equipment manufacturers and original design manufacturers. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington.

NASDAQ ended the session with MicroVision falling 28.57% to $4.55 on Wednesday, following the last session’s upward trend. NASDAQ rose 0.39% to $13,626.48, after four consecutive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, MicroVision has a trailing twelve months EPS of $-0.32.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -62.05%.

Volatility

MicroVision’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.62%, a positive 4.94%, and a positive 5.22%.

MicroVision’s highest amplitude of average volatility was 7.03% (last week), 8.36% (last month), and 5.22% (last quarter).

Earnings Before Interest, Taxes, Depreciation, and Amortization

MicroVision’s EBITDA is 1.03.

More news about MicroVision.

2. Methes Energies International Ltd (MEIL) – -18.89%

Methes Energies International Ltd., a renewable energy company, produces and sells biodiesel fuel and biodiesel processing equipment in the United States and Canada. It offers Denami biodiesel processors. The company also produces glycerin and offer services related to the production of biodiesel, as well as purchases and sells feedstock. It sells its products and services to a network of biodiesel fuel producers. The company was founded in 2004 and is headquartered in Las Vegas, Nevada.

NASDAQ ended the session with Methes Energies International Ltd dropping 18.89% to $0.02 on Wednesday, following the last session’s downward trend. NASDAQ jumped 0.39% to $13,626.48, after four sequential sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Methes Energies International Ltd has a trailing twelve months EPS of $-0.35.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -61.54%.

More news about Methes Energies International Ltd.

3. Ocular Therapeutix (OCUL) – -16.38%

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

NASDAQ ended the session with Ocular Therapeutix falling 16.38% to $5.31 on Wednesday, after three successive sessions in a row of losses. NASDAQ jumped 0.39% to $13,626.48, after four sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Ocular Therapeutix has a trailing twelve months EPS of $-1.12.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -198.45%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 1.4%, now sitting on 51.68M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Ocular Therapeutix’s EBITDA is 9.25.

Volume

Today’s last reported volume for Ocular Therapeutix is 5440250 which is 420.09% above its average volume of 1046010.

Yearly Top and Bottom Value

Ocular Therapeutix’s stock is valued at $5.31 at 17:32 EST, way below its 52-week high of $7.96 and way above its 52-week low of $2.57.

More news about Ocular Therapeutix.

4. Humana (HUM) – -12.74%

Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of PBM business. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

NYSE ended the session with Humana dropping 12.74% to $447.33 on Wednesday while NYSE slid 0.16% to $15,642.73.

: humana leads S&P 500 decliners after unitedhealth says seniors are catching up on pandemic-delayed surgeriesThe stock led S&P 500 decliners, as Oppenheimer said if the trend is widespread, Humana may be most exposed as it it has a larger Medicare Advantage presence. , Analysts noted, however, that Humana has not commented of late and that peers have also not drawn attention to pressure on their businesses.

Earnings Per Share

As for profitability, Humana has a trailing twelve months EPS of $24.64.

PE Ratio

Humana has a trailing twelve months price to earnings ratio of 18.15. Meaning, the purchaser of the share is investing $18.15 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.45%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 2.9% and 10.3%, respectively.

Previous days news about Humana

• Humana (hum) wins contract to serve Oklahoma's medicaid members. According to Zacks on Monday, 12 June, "Apart from a solid Medicaid foothold, Humana continues to occupy a significant share of the health insurance market in Oklahoma through other business lines. ", "Shares of Humana have gained 20.4% in a year compared with the industry’s 7.3% growth. "

More news about Humana.

5. Logitech (LOGI) – -11.03%

Logitech International S.A., through its subsidiaries, designs, manufactures, and markets products that connect people to working, creating, gaming, and streaming worldwide. The company offers pointing devices, such as wireless mouse; corded and cordless keyboards, living room keyboards, and keyboard-and-mouse combinations; PC webcams; and keyboards for tablets and smartphones, as well as other accessories for mobile devices. It also provides keyboards, mice, headsets, and simulation products, such as gamepads, steering wheels, simulation controllers, console gaming headsets, and streamlabs services; video conferencing products, such as ConferenceCams, which combine enterprise-quality audio and high-definition video to bring video conferencing to businesses of any size; webcams and headsets that turn desktop into collaboration space; and controller for video conferencing room solutions. In addition, the company offers portable wireless Bluetooth and Wi-Fi connected speakers, mobile speakers, PC speakers, PC headsets, microphones, in-ear headphones, and wireless audio wearables. Its channel network includes consumer electronics distributors, retailers, e-tailers, computer and telecommunications stores, value-added resellers, and online merchants. The company sells its products under the Logitech, Logitech G, ASTRO Gaming, Streamlabs, Blue Microphones, and Ultimate Ears brands. Logitech International S.A. was incorporated in 1981 and is headquartered in Lausanne, Switzerland.

NASDAQ ended the session with Logitech dropping 11.03% to $56.85 on Wednesday while NASDAQ jumped 0.39% to $13,626.48.

Earnings Per Share

As for profitability, Logitech has a trailing twelve months EPS of $2.23.

PE Ratio

Logitech has a trailing twelve months price to earnings ratio of 25.49. Meaning, the purchaser of the share is investing $25.49 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.66%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Sep 25, 2022, the estimated forward annual dividend rate is 0.97 and the estimated forward annual dividend yield is 1.54%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Logitech’s EBITDA is 1.98.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Logitech’s stock is considered to be oversold (<=20).

More news about Logitech.

6. American Public Education (APEI) – -10.85%

American Public Education, Inc., together with its subsidiaries, provides online and campus-based postsecondary education and career learning. It operates through three segments: American Public University System, Rasmussen University, and Hondros College of Nursing. The company offers 136 degree programs and 115 certificate programs in various fields of study, including nursing, public health, public administration, and business administration. It also provides nursing-and health sciences-focused postsecondary education, diploma in practical nursing, and an associate degree in nursing. The company was incorporated in 1991 and is headquartered in Charles Town, West Virginia.

NASDAQ ended the session with American Public Education dropping 10.85% to $4.52 on Wednesday while NASDAQ rose 0.39% to $13,626.48.

Earnings Per Share

As for profitability, American Public Education has a trailing twelve months EPS of $-6.29.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -32.91%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

American Public Education’s EBITDA is 0.37.

Volatility

American Public Education’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.10%, a negative 0.32%, and a positive 4.11%.

American Public Education’s highest amplitude of average volatility was 3.87% (last week), 3.81% (last month), and 4.11% (last quarter).

Moving Average

American Public Education’s worth is way under its 50-day moving average of $5.69 and way below its 200-day moving average of $9.79.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, American Public Education’s stock is considered to be oversold (<=20).

More news about American Public Education.

7. FuelCell Energy (FCEL) – -8.06%

FuelCell Energy, Inc., together with its subsidiaries, manufactures and sells stationary fuel cell energy platforms that decarbonize power and produce hydrogen. It offers SureSource 1500, a 1.4-megawatt (MW) platform; SureSource 3000, a 2.8 MW platform; SureSource 4000, a 3.7 MW platform; SureSource 250, a 250- kilowatt (kW) platform; SureSource 400, a 400-kW platform; and SureSource Hydrogen, a 2.3 MW platform that is designed to produce up to 1,200 kilograms of hydrogen per day for multi-megawatt utility, microgrid, and distributed hydrogen applications, as well as on-site heat and chilling applications. The company also provides SureSource platform in various configurations and applications, including on-site power, utility grid support, and microgrid, as well as distributed hydrogen; solutions for long duration hydrogen-based energy storage and electrolysis technology; and carbon capture, separation, and utilization systems. Its SureSource power plants generate electricity, heat, hydrogen, and water. In addition, the company provides turn-key solutions, including development, engineering, procurement, construction, interconnection, and operation services. It serves various markets, including utilities and independent power producers, industrial and process applications, education and health care, data centers and communication, wastewater treatment, government, microgrids, hydrogen transportation, food and beverage, and commercial and hospitality. The company primarily operates in the United States, South Korea, England, Germany, and Switzerland. FuelCell Energy, Inc. was founded in 1969 and is headquartered in Danbury, Connecticut.

NASDAQ ended the session with FuelCell Energy falling 8.06% to $2.57 on Wednesday while NASDAQ jumped 0.39% to $13,626.48.

Earnings Per Share

As for profitability, FuelCell Energy has a trailing twelve months EPS of $-0.31.

Sales Growth

FuelCell Energy’s sales growth is negative 25.8% for the current quarter and negative 6% for the next.

Moving Average

FuelCell Energy’s worth is way above its 50-day moving average of $2.26 and way under its 200-day moving average of $3.10.

More news about FuelCell Energy.

8. CVS Health (CVS) – -7.11%

CVS Health Corporation provides health services in the United States. It operates through Health Care Benefits, Pharmacy Services, and Retail/LTC segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail-order, mail-order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.

NYSE ended the session with CVS Health falling 7.11% to $67.12 on Wednesday while NYSE slid 0.16% to $15,642.73.

Earnings Per Share

As for profitability, CVS Health has a trailing twelve months EPS of $3.01.

PE Ratio

CVS Health has a trailing twelve months price to earnings ratio of 22.3. Meaning, the purchaser of the share is investing $22.3 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.42%.

Yearly Top and Bottom Value

CVS Health’s stock is valued at $67.12 at 17:32 EST, way under its 52-week high of $107.26 and above its 52-week low of $66.34.

Moving Average

CVS Health’s value is under its 50-day moving average of $71.84 and way below its 200-day moving average of $87.10.

Revenue Growth

Year-on-year quarterly revenue growth grew by 10.8%, now sitting on 329.92B for the twelve trailing months.

More news about CVS Health.

9. Aurora Cannabis (ACB) – -7.05%

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, Caribbeans, South America, and Israel; and distribution and sale of hemp-derived cannabidiol (CBD) products in the United States (U.S.) market. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, and cannabis extracts, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried milled strains and strain specific cannabis oils. Further, it offers patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

NYSE ended the session with Aurora Cannabis falling 7.05% to $0.54 on Wednesday while NYSE slid 0.16% to $15,642.73.

Earnings Per Share

As for profitability, Aurora Cannabis has a trailing twelve months EPS of $-6.19.

Volatility

Aurora Cannabis’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.48%, a negative 0.01%, and a positive 2.92%.

Aurora Cannabis’s highest amplitude of average volatility was 3.10% (last week), 3.46% (last month), and 2.92% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Aurora Cannabis’s stock is considered to be oversold (<=20).

More news about Aurora Cannabis.

10. FibroGen (FGEN) – -6.95%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen falling 6.95% to $16.34 on Wednesday while NASDAQ jumped 0.39% to $13,626.48.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-3.34.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -411.93%.

More news about FibroGen.

Stay up to date with our winners and losers daily report